Velomedix Inc. has raised $9.3 million in combined equity and debt financing, according to a regulatory filing. The development stage medical device company was created to realize the clinical potential of mild therapeutic hypothermia in benefiting patients suffering from ischemic and reperfusion injury effects of cardiac arrest, heart attack, stroke and traumatic brain injury.

Seventeen separate investors participated in the offering. Velomedix is backed by investors including Longitude Capital.